X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21) 21
oncology (20) 20
female (19) 19
aged (18) 18
index medicus (16) 16
middle aged (16) 16
male (15) 15
chemotherapy (14) 14
adult (13) 13
lung neoplasms - drug therapy (11) 11
lung neoplasms - genetics (9) 9
carcinoma, non-small-cell lung - drug therapy (8) 8
carcinoma, non-small-cell lung - genetics (8) 8
disease-free survival (8) 8
lung neoplasms - pathology (8) 8
treatment outcome (8) 8
aged, 80 and over (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
lung neoplasms - mortality (7) 7
receptor, epidermal growth factor - genetics (7) 7
breast cancer (6) 6
carcinoma, non-small-cell lung - mortality (6) 6
carcinoma, non-small-cell lung - pathology (6) 6
gefitinib (6) 6
mutation (6) 6
respiratory system (6) 6
survival (6) 6
care and treatment (5) 5
cisplatin - administration & dosage (5) 5
erlotinib (5) 5
hematology, oncology and palliative medicine (5) 5
lung cancer (5) 5
neoplasm staging (5) 5
product development (5) 5
adenocarcinoma (4) 4
antineoplastic agents - therapeutic use (4) 4
cancer (4) 4
carboplatin (4) 4
cell lung-cancer (4) 4
cisplatin (4) 4
clinical trials (4) 4
deoxycytidine - administration & dosage (4) 4
deoxycytidine - analogs & derivatives (4) 4
disease progression (4) 4
erlotinib hydrochloride (4) 4
kaplan-meier estimate (4) 4
lung cancer, non-small cell (4) 4
medicine & public health (4) 4
medicine, general & internal (4) 4
prognosis (4) 4
proportional hazards models (4) 4
prospective studies (4) 4
protein kinase inhibitors - therapeutic use (4) 4
pulmonary/respiratory (4) 4
quinazolines - therapeutic use (4) 4
radiotherapy (4) 4
retrospective studies (4) 4
survival rate (4) 4
taxoids - administration & dosage (4) 4
acquired-resistance (3) 3
adenocarcinoma - drug therapy (3) 3
alk (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
carcinoma, squamous cell - pathology (3) 3
combined modality therapy (3) 3
crizotinib (3) 3
dermatology (3) 3
docetaxel (3) 3
drug administration schedule (3) 3
lung carcinoma (3) 3
lung neoplasms - therapy (3) 3
melanoma (3) 3
metastases (3) 3
multivariate analysis (3) 3
neoadjuvant treatment (3) 3
nsclc (3) 3
prognostic factors (3) 3
protein kinase inhibitors - adverse effects (3) 3
quinazolines - administration & dosage (3) 3
sensitivity (3) 3
spain (3) 3
survival analysis (3) 3
therapy (3) 3
time factors (3) 3
women (3) 3
1st-line treatment (2) 2
abridged index medicus (2) 2
activating mutations (2) 2
adenocarcinoma - genetics (2) 2
adenocarcinoma - mortality (2) 2
adenocarcinoma - pathology (2) 2
adenocarcinoma - therapy (2) 2
adolescent (2) 2
afatinib (2) 2
american joint committee (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
association (2) 2
biomarkers, tumor (2) 2
biomarkers, tumor - genetics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Rosell, Rafael, Dr and Carcereny, Enric, MD and Gervais, Radj, MD and Vergnenegre, Alain, Prof and Massuti, Bartomeu, MD and Felip, Enriqueta, MD and Palmero, Ramon, MD and Garcia-Gomez, Ramon, MD and Pallares, Cinta, MD and Sanchez, Jose Miguel, MD and Porta, Rut, MD and Cobo, Manuel, MD and Garrido, Pilar, MD and Longo, Flavia, MD and Moran, Teresa, MD and Insa, Amelia, MD and De Marinis, Filippo, MD and Corre, Romain, MD and Bover, Isabel, MD and Illiano, Alfonso, MD and Dansin, Eric, MD and de Castro, Javier, MD and Milella, Michele, MD and Reguart, Noemi, MD and Altavilla, Giuseppe, MD and Jimenez, Ulpiano, MD and Provencio, Mariano, MD and Moreno, Miguel Angel, MD and Terrasa, Josefa, MD and Muñoz-Langa, Jose, MD and Valdivia, Javier, MD and Isla, Dolores, MD and Domine, Manuel, MD and Molinier, Olivier, MD and Mazieres, Julien, Prof and Baize, Nathalie, MD and Garcia-Campelo, Rosario, MD and Robinet, Gilles, MD and Rodriguez-Abreu, Delvys, MD and Lopez-Vivanco, Guillermo, MD and Gebbia, Vittorio, MD and Ferrera-Delgado, Lioba, MD and Bombaron, Pierre, MD and Bernabe, Reyes, MD and Bearz, Alessandra, MD and Artal, Angel, MD and Cortesi, Enrico, MD and Rolfo, Christian, MD and Sanchez-Ronco, Maria, PhD and Drozdowskyj, Ana, PhD and Queralt, Cristina, PhD and de Aguirre, Itziar, PhD and Ramirez, Jose Luis, PhD and Sanchez, Jose Javier, Prof and Molina, Miguel Angel, PhD and Taron, Miquel, PhD and Paz-Ares, Luis, MD and Assoc Italiana Oncologia Toracica and Grp Francais Pneumocancerologie and Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 958 - 967
Journal Article
Journal Article
by Paz-Ares, Luis and Dvorkin, Mikhail and Chen, Chengshui and Chen, Yen-Hsun and Chen, Yuan and Chen, Yuanbin and Chen, Zhendong and Reinmuth, Niels and Hotta, Katsuyuki and Trukhin, Dmytro and Statsenko, Galina and Hochmair, Maximilian J and Özgüroğlu, Mustafa and Ji, Jun Ho and Voitko, Nataliia and Voitko, Oleksandr and Poltoratskiy, Artem and Ponce, Santiago and Verderame, Francesco and Havel, Libor and Bondarenko, Igor and Kazarnowicz, Andrzej and Losonczy, György and Conev, Nikolay V and Armstrong, Jon and Byrne, Natalie and Shire, Norah and Jiang, Haiyi and Goldman, Jonathan W and Batagelj, Emilio and Casarini, Ignacio and Pastor, Anea Viviana and Sena, Susana Noemi and Zarba, Juan Jose and Burghuber, Otto and Hartl, Sylvia and Lamprecht, Bernd and Studnicka, Michael and Alberto Schlittler, Luis and Augusto Martinelli de Oliveira, Fabricio and Calabrich, Aknar and Colagiovanni Girotto, Gustavo and Dos Reis, Peo and Fausto Nino Gorini, Carlos and Rafael Martins De Marchi, Peo and Serodio da Rocha Baldotto, Clarissa and Sette, Claudia and Zukin, Mauro and Dudov, Assen and Ilieva, Rumyana and Koynov, Krassimir and Krasteva, Rositsa and Tonev, Ivan and Valev, Spartak and Venkova, Violetka and Bi, Minghong and Fang, Jian and Feng, Jifeng and Han, Zhigang and Hu, Jie and Hu, Yi and Li, Wei and Li, Chien-Te and Liang, Zongan and Lin, Zhong and Ma, Shenglin and Ma, Rui and Nan, Kejun and Shu, Yongqian and Wang, Chin-Chou and Wang, Kai and Wang, Mengzhao and Wu, Gang and Wu, Shang-Yin and Yang, Nong and Yang, Zhixiong and Zhang, Wei and Zhang, Helong and Zhao, Yanqiu and Zhao, Jun and Zhou, Jianying and Zhou, Caicun and Zhou, Xiangdong and Kolek, Vitezslav and Koubkova, Leona and Roubec, Jaromir and Skrickova, Jana and Zemanova, Milada and Chouaid, Christos and Hilgers, Werner and Lena, Hervé and Moro-Sibilot, Denis and Robinet, Gilles and Souquet, Pierre-Jean and Alt, Jürgen and Bischoff, Helge and Grohe, Christian and Laack, Eckart and Lang, Susanne and Panse, Jens and ... and CASPIAN Investigators and CASPIAN investigators
The Lancet, ISSN 0140-6736, 11/2019, Volume 394, Issue 10212, pp. 1929 - 1939
Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has... 
PROPHYLACTIC CRANIAL IRRADIATION | SCLC | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | CISPLATIN | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Etoposide - adverse effects | Drug Administration Schedule | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols | Carboplatin - administration & dosage | Etoposide - administration & dosage | Male | Small Cell Lung Carcinoma - drug therapy | Cisplatin - administration & dosage | Carboplatin - adverse effects | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal - administration & dosage | Progression-Free Survival | Cisplatin - adverse effects | Female | Small Cell Lung Carcinoma - mortality | Aged | Etoposide | Care and treatment | Product development | Lung cancer | Analysis | Drugs | Medical services | Radiation | Clinical trials | Metastasis | Cancer therapies | Randomization | Motivation | Platinum | Immunotherapy | Safety | Neutropenia | Small cell lung carcinoma | Maintenance | Radiation therapy | Survival | Patients | Cisplatin | Response rates | Carboplatin | Irradiation | Ligands | Clinical medicine | Solid tumors | Tumors | Apoptosis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2007, Volume 25, Issue 30, pp. 4736 - 4742
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2011, Volume 17, Issue 5, pp. 1160 - 1168
Journal Article
Lung Cancer, ISSN 0169-5002, 2014, Volume 84, Issue 2, pp. 161 - 167
Abstract Objectives Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone deacetylase inhibitor with demonstrated antiproliferative effects... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | TKIs resistance | EGFR mutations | Erlotinib | NSCLC | Histone deacetylase inhibitors | Vorinostat | HISTONE DEACETYLASE INHIBITOR | GEFITINIB | CARBOPLATIN | HEAT-SHOCK-PROTEIN-90 | SUBEROYLANILIDE HYDROXAMIC ACID | ACQUIRED-RESISTANCE | SENSITIVITY | KINASE INHIBITORS | E-CADHERIN | CHAPERONE FUNCTION | ONCOLOGY | RESPIRATORY SYSTEM | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Mutation, Missense | Hydroxamic Acids - administration & dosage | Adult | Female | Quinazolines - administration & dosage | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Treatment Outcome | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Drug Synergism | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Epidermal growth factor | Clinical trials | Heat shock proteins | Product development | Genetic aspects | Lung cancer, Non-small cell | Index Medicus
Journal Article
Lung Cancer, ISSN 0169-5002, 2017, Volume 108, pp. 154 - 160
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 09/2019, Volume 79, Issue 17, pp. 4439 - 4452
Although EGFR mutant-selective tyrosine kinase inhibitors (TKI) are clinically effective, acquired resistance can occur by reactivating ERK. We show using in... 
CELL LUNG-CANCER | EPITHELIAL-MESENCHYMAL TRANSITION | GEFITINIB | ONCOLOGY | IN-VIVO | ACQUIRED-RESISTANCE | SENSITIVITY | CHEMOKINE RECEPTOR CXCR7 | DRUG-RESISTANCE | EMT | MUTANT EGFR
Journal Article